Official Publication of Health Promotion Research Center
Image Credit:Health Scope
Outline
The Necessity of Enhanced Harm Reduction Programs to Prevent Blood-Borne Infections Amongst Injection Drug Users
Authors
Footnotes
Authors’ Contribution:Mahmodreza Miri-Bonjar participated in the manuscript writing and drafted the manuscript; Alireza Khorram researched and wrote the manuscript; and Alireza Ansari-Moghaddam participated in the manuscript writing and revised the manuscript.
References
- 1.Saigi N, Espelt A, Folch C, Sarasa-Renedo A, Castellano Y, Majo X, et al. Differences in illegal drug consumption between native and immigrants in a large sample of injected drug users in Catalonia (Spain). Adicciones. 2014;26(1):69-76. [PubMed ID: 24652401].
- 2.Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One. 2014;9(8). eee104515. [PubMed ID: 25110927]. https://doi.org/10.1371/journal.pone.0104515.
- 3.Philbin MM, FuJie Z. Exploring stakeholder perceptions of facilitators and barriers to using needle exchange programs in Yunnan Province, China. PLoS One. 2014;9(2). eee86873. [PubMed ID: 24498286]. https://doi.org/10.1371/journal.pone.0086873.
- 4.Huang YF, Yang JY, Nelson KE, Kuo HS, Lew-Ting CY, Yang CH, et al. Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts. PLoS Med. 2014;11(4). eee1001625. [PubMed ID: 24714449]. https://doi.org/10.1371/journal.pmed.1001625.
- 5.Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, et al. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med. 2014;11(6). eee1001663. [PubMed ID: 24937136]. https://doi.org/10.1371/journal.pmed.1001663.
- 6.Wodak A, McLeod L. The role of harm reduction in controlling HIV among injecting drug users. Aids. 2008;22 Suppl 2:S81-92. [PubMed ID: 18641473]. https://doi.org/10.1097/01.aids.0000327439.20914.33.
- 7.Edmonton AB. Working with people who use drugs: A harm reduction approach. Non Prescription Needle Use Initiativ. Edmonton: Canadian Liver Foundation; 2007. Available from: http://www.liver.ca/files/PDF/Publications_English/Working_with_People_who_Use_Drugs-A_Harm_Reduction_Approach_Manual_and_all_supplements.pdf.
- 8.Barbeau A, Breton G, Lemieux B, Butterworth RF. Bilirubin metabolism - preliminary investigation. Can J Neurol Sci. 1976;3(4):365-72. [PubMed ID: 1000423].
- 9.Thomson N. Harm reduction history, response, and current trends in Asia. J Food Drug Anal. 2013;21(4):S113-6. [PubMed ID: 25264414]. https://doi.org/10.1016/j.jfda.2013.09.047.
Copyright
Copyright © 2016, Health Promotion Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Similar Articles
The Effect of Harm-reducing Programs in Drop-in Centers on the Frequency of High-Risk Behaviors Among Injecting Drug Users in Hamadan
Moradi A, Ranjbaran H, Moradi M, Amjadian M. The Effect of Harm-reducing Programs in Drop-in Centers on the Frequency of High-Risk Behaviors Among Injecting Drug Users in Hamadan. Shiraz E-Med J. 2023;24(5):e132283. doi: https://doi.org/10.5812/semj-132283
Reduction in Prevalence of Hepatitis B Surface Antigen Among Intravenous Drug Users in Tehran Drop-in-Centers
kandelouei T, Hosseini SM, Gachkar L, Keyvani H, Davoodbeglou F, et al. Reduction in Prevalence of Hepatitis B Surface Antigen Among Intravenous Drug Users in Tehran Drop-in-Centers. Arch Clin Infect Dis. 2013;8(2):e15531. doi: https://doi.org/10.5812/archcid.15531
Norjizak Injection: A Critical Risk for Transmitting Blood-Borne Infectious Diseases
Alam Mehrjerdi Z. Norjizak Injection: A Critical Risk for Transmitting Blood-Borne Infectious Diseases. Hepat Mon. 2013;13(4):e8272. doi: https://doi.org/10.5812/hepatmon.8272
Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran
Sharhani A, Mehrabi Y, Noroozi A, Nasirian M, Higgs P, et al. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran. Hepat Mon. 2017;17(10):e58739. doi: https://doi.org/10.5812/hepatmon.58739
Intravenous Drug Use: the Predominant Risk Factors for Hepatitis C Virus Infection
Fallahian F, Najafi A, Alavian S. Intravenous Drug Use: the Predominant Risk Factors for Hepatitis C Virus Infection. Shiraz E-Med J. 2010;11(4):20443. doi:
More by these authors
- Scopus by DOI: 0
Last Update: 6 days ago
- Scopus by Title: 0
Last Update: 6 days ago
- Scopus by Title (Ref): 2
Last Update: 6 days ago
- CrossRef: 0
Last Update: 2 hours ago
- OpenAlex: 1
Last Update: 2 days ago
- OpenCitations: 0
Last Update: 4 days ago